Portola Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) failed to approve AndexXa, the Xarelto antidote currently in development for uncontrollable bleeds. Currently, there is no reversal agent for uncontrolled bleeding associated with the anticoagulants Xarelto or Eliquis which have been linked […]
Oct 11, 2016
By Jessica Hoerman
Xarelto
